Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Join | Sign in
Home>Terms & Conditions
  Terms & Conditions


Press Releases & Product Announcements

Please send all press releases and product announcements to pr@technologynetworks.com Wherever possible, press releases should be emailed as a Microsoft Word attachment or embedded in the email itself. Images should be sent as separate attachments. Where possible please insert the name(s) of the community(ies) that you wish the press release to be published on into the subject line of the email.

For a full list of all Technology Networks’ communities please click here

Submitting Application Notes

By submitting your application notes to us for online publication you are agreeing to the Terms and Conditions for the application notes section of Technology Networks' communities and, confirming that you have the required copyright to submit these application notes.

Application notes should be submitted to apps@technologynetworks.com preferably as a PDF, if not as a Microsoft Publisher or PowerPoint file. A 40 - 70 word summary must be sent with each application note submitted.

The name(s) of the website(s) that you wish the application note to be published on should be entered into the subject line of the email. For a full list of all Technology Networks’ communities please click here

Before submitting an application note for online publication please read the terms and conditions below.

Submitting a Poster

Posters submitted by academics and from not-for-profit organizations will be published free of charge. For commercial companies there will be an administration charge of $200 for each poster published. Please contact Kelly Giles for more information.

By submitting your poster to us for online publication you are agreeing to the Terms and Conditions for the Posters section of Technology Networks' communities and confirming that you have the required copyright to submit these posters.

Posters should be submitted using the online submission form which is located within the posters section of each website, (click “submit poster” link). The poster needs to be submitted as a PDF or Microsoft PowerPoint file. A 40 – 70 word summary must be submitted along with the poster.

If you have any problems with you submission, please contact posters@technologynetworks.com, stating the name of the website you wish to publish your poster on in the subject line.

Before submitting a poster for online publication please read the terms and conditions below.

TERMS AND CONDITIONS

1. Services / Consideration.
Technology Networks Ltd. ('TechNet') shall develop an electronic version of the printed Application Note or Poster that has been created from the files provided by you (the 'Author'). In consideration of TechNet's development, archiving and retrieval of the Author's Application note, Author shall: (a) grant the license stated in Section 3.

2. Copyright Ownership.
As between TechNet and Author, Author shall be the owner of all copyrights in and to the content contained in the Print Application Note or poster and the online Application Note or Poster.

3. Copyright License.
In order for TechNet to electronically archive, display and distribute the Application Note or Poster, Author hereby grants to TechNet an irrevocable, perpetual license to maintain, store, cache, copy and distribute (in any current or future media) the Application Note or Poster (the 'License Grant'). The License Grant includes TechNet's right to include the Application Note or Poster in its current and future database or databases as well as to distribute the Application Note or Poster electronically to third parties through any one or more websites operated by or on behalf of TechNet.

4.Representations and Warranties.
Author hereby represents and warrants to TechNet that: (i) Author is the owner or authorized licensee of all right, title and interest (including all copyrights and other intellectual property rights) in and to all content that appears on the Application Note or Poster; (ii) all content that appears in the Application Note or Poster is the Author's original work and contains no libelous or unlawful statements, does not infringe on the rights or privacy of others or contain material or instructions that might cause harm or injury, (iii) Author's execution and performance of this Agreement does not and shall not constitute a breach of, or otherwise violate, any written or verbal understanding or agreement between Author and any third party; and (iv) TechNet's use of the files provided by the Author to create the Application Note or Poster, as well as TechNet's exercise of its rights pursuant to the License Grant, shall not infringe or violate the copyrights, or other intellectual property rights, of any third party.

5.Miscellaneous.
(a) This Agreement shall be construed and enforced in accordance with the laws of the United Kingdom. Each party hereby consents to the exclusive jurisdiction and venue of any court located in the United Kingdom with respect to any claim or controversy arising out of or related to this Agreement.

(b) This Agreement: (i) shall benefit and bind each party and their successors and assigns; (ii) contains the entire understanding and agreement of the parties; and it incorporates or supersedes all other written or verbal agreements and understandings with respect to the subject matter; and (iii) may be amended or modified only in writing signed by both parties and referring specifically to the Agreement.

Scientific News
Gene Therapy for Cystic Fibrosis Shows Encouraging Trial Results
A therapy that replaces the faulty gene responsible for cystic fibrosis in patients' lungs has produced encouraging results in a major UK trial.
In Blinding Eye Disease, Trash-Collecting Cells Go Awry, Accelerate Damage
NIH research points to microglia as potential therapeutic target in retinitis pigmentosa.
Boys More Likely to Have Antipsychotics Prescribed, Regardless of Age
NIH-funded study is the first look at antipsychotic prescriptions patterns in the U.S.
Human Trials of Manufactured Blood Within Two Years
The first human trials of lab-produced blood to help create better-matched blood for patients with complex blood conditions has been announced by NHS Blood and Transplant.
New Medication for Alcohol Use Disorder
NIH begins clinical trial investigating a potential treatment for alcohol use disorder.
Behavior Matters: Redesigning the Clinical Trial
A recent meta-analysis of six such clinical trials shows that behavior can have a serious impact on the effectiveness of a treatment and that the currently used DBRCT procedures may not be able to assess the effects of behavior on the treatment.
New Commercial Method for Producing Medical Isotope
The effort to secure a stable, domestic source of a critical medical isotope reached an important milestone this month as scientists demonstrated the production, separation and purification of molybdenum-99 (Mo-99.
NCI-MATCH Trial will Link Targeted Cancer Drugs to Gene Abnormalities
Precision medicine trial will open to patient enrollment in July.
Linking Targeted Cancer Drugs to Gene Abnormalities
Investigators at the NIH have announced a series of clinical trials that will study drugs or drug combinations that target specific genetic mutations.
IAOCR Welcomes Important Initial Step for Regulating European Clinical Trials
New regulation to ensure a more streamlined risk-based approach to the conduct of trials with more public openness about each trial and the results they produce.
Scroll Up
Scroll Down
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters